Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
about
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Secukinumab demonstrates great ...... results from the CLEAR study.
@en
Secukinumab demonstrates great ...... results from the CLEAR study.
@nl
type
label
Secukinumab demonstrates great ...... results from the CLEAR study.
@en
Secukinumab demonstrates great ...... results from the CLEAR study.
@nl
prefLabel
Secukinumab demonstrates great ...... results from the CLEAR study.
@en
Secukinumab demonstrates great ...... results from the CLEAR study.
@nl
P2093
P2860
P356
P1476
Secukinumab demonstrates great ...... results from the CLEAR study.
@en
P2093
A Blauvelt
E Davenport
F Vanaclocha
I Gilloteau
N Williams
W Abramovits
P2860
P304
P356
10.1111/JDV.14391
P50
P577
2017-06-11T00:00:00Z